How Merck Gets To $51 Billion: Oncology or Vaccines?
- Friday, March 20, 2020, 7:14
- Market
- Add a comment
Merck (NYSE: MRK) revenue grew from $39.8 billion in 2016 to $46.8 billion in 2019, and it is estimated to top $51.5 billion in 2020, primarily driven by its oncology drug, Keytruda, according to our estimates. The company’s oncology drugs will account for 32% of the company’s total sales in 2020…
About the Author
admin123 has written 23527 stories on this site.
